Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

   Active, not recruiting · Phase 2 · Melanoma

   NCT03897881 · ModernaTX, Inc. · 20 U.S. investigators

   $1.7Mresearch payments

2. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   Recruiting · Phase 2 · Advanced Solid Tumor

   NCT06172478 · Daiichi Sankyo Inc. · 12 U.S. investigators

   $1.7Mresearch payments

3. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

   Active, not recruiting · Phase 3 · Multiple Myeloma

   NCT06158841 · AbbVie Inc. · 48 U.S. investigators

   $1.7Mresearch payments

4. Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

   Completed · Phase 3 · Rheumatoid Arthritis

   NCT05814627 · AbbVie Inc. · 78 U.S. investigators

   $1.7Mresearch payments

5. Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

   Active, not recruiting · Phase 4 · Asthma

   NCT06572228 · Regeneron Pharmaceuticals, Inc. · 54 U.S. investigators

   $1.7Mresearch payments

6. A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

   Active, not recruiting · Phase 2 · Episodic Migraine

   NCT06625060 · Ipsen Innovation · 36 U.S. investigators

   $1.7Mresearch payments

7. Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

   Recruiting · Phase 3 · Schizophrenia

   NCT05303064 · Alkermes, Inc. · 26 U.S. investigators

   $1.7Mresearch payments

8. A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

   Active, not recruiting · Phase 4 · Eosinophilic Oesophagitis

   NCT06101095 · Genzyme Corporation · 15 U.S. investigators

   $1.7Mresearch payments

9. Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

   Completed · Phase 2, Phase 3 · Advanced or Metastatic Solid Malignancies

   NCT04887870 · Mirati Therapeutics, Inc. · 8 U.S. investigators

   $1.7Mresearch payments

10. OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

    Recruiting · Phase 3 · Vision Loss Night

    NCT07140783 · Oyster Point Pharma, Inc. · 32 U.S. investigators

    $1.7Mresearch payments

11. A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

    Active, not recruiting · Phase 1 · Pancreatic Ductal Adenocarcinoma

    NCT06607185 · Eli Lilly and Company · 22 U.S. investigators

    $1.6Mresearch payments

12. A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

    Recruiting · Phase 3 · Systemic Lupus Erythematosus

    NCT06617325 · UCB SA · 52 U.S. investigators

    $1.6Mresearch payments

13. A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

    Active, not recruiting · Phase 2 · Metastatic Colorectal Cancer

    NCT06614192 · AbbVie Inc. · 37 U.S. investigators

    $1.6Mresearch payments

14. A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

    Recruiting · Phase 3 · Obesity

    NCT06439277 · Eli Lilly and Company · 23 U.S. investigators

    $1.6Mresearch payments

15. A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

    Active, not recruiting · Phase 3 · Chronic Graft Versus Host Disease

    NCT06143891 · Sanofi US Services Inc. · 25 U.S. investigators

    $1.6Mresearch payments

16. A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants

    Completed · Phase 3 · Masseter Muscle Prominence

    NCT06399718 · AbbVie Inc. · 20 U.S. investigators

    $1.6Mresearch payments

17. Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

    Active, not recruiting · Phase 3 · Metastatic Non Small Cell Lung Cancer

    NCT05215340 · Daiichi Sankyo Inc. · 29 U.S. investigators

    $1.6Mresearch payments

18. A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

    Completed · Phase 3 · Respiratory Syncytial Virus

    NCT07117487 · ModernaTX, Inc. · 11 U.S. investigators

    $1.6Mresearch payments

19. A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

    Recruiting · Phase 1 · Glioblastoma Multiforme

    NCT05303467 · Boston Scientific Corporation · 5 U.S. investigators

    $1.6Mresearch payments

20. A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

    Active, not recruiting · Phase 3 · Ulcerative Colitis

    NCT06880744 · AbbVie Inc. · 66 U.S. investigators

    $1.6Mresearch payments

21. A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

    Completed · Phase 1, Phase 2 · Lyme Disease

    NCT05975099 · ModernaTX, Inc. · 20 U.S. investigators

    $1.6Mresearch payments

22. Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

    Recruiting · Phase 3 · Cutaneous Squamous Cell Carcinoma (CSCC)

    NCT06585410 · Regeneron Pharmaceuticals, Inc. · 33 U.S. investigators

    $1.6Mresearch payments

23. A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

    Completed · Phase 2, Phase 3 · SARS-CoV-2

    NCT04649151 · ModernaTX, Inc. · 20 U.S. investigators

    $1.6Mresearch payments

24. The PEERLESS II Study

    Completed · Not applicable · Pulmonary Embolism

    NCT06055920 · Stryker Corporation · 11 U.S. investigators

    $1.6Mresearch payments

25. Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

    Active, not recruiting · Phase 3 · Primary Biliary Cirrhosis

    NCT04526665 · Ipsen Bioscience Inc. · 51 U.S. investigators

    $1.6Mresearch payments

26. A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants

    Completed · Phase 1 · Healthy Volunteers

    NCT07007091 · AbbVie Inc. · 1 U.S. investigator

    $1.6Mresearch payments

27. Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

    Completed · Phase 3 · Renal Cell Carcinoma

    NCT04987203 · Aveo Pharmaceuticals, Inc. · 39 U.S. investigators

    $1.6Mresearch payments

28. A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

    Active, not recruiting · Phase 2 · Plasma Cell Myeloma Refractory

    NCT06356571 · Genzyme Corporation · 17 U.S. investigators

    $1.5Mresearch payments

29. ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

    Recruiting · Phase 1, Phase 2 · Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

    NCT06430385 · Ionis Pharmaceuticals, Inc. · 6 U.S. investigators

    $1.5Mresearch payments

30. A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

    Completed · Phase 3 · Type 2 Diabetes

    NCT06109311 · Eli Lilly Export S.a. Puerto Rico Branch · 37 U.S. investigators

    $1.5Mresearch payments

31. A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

    Completed · Phase 3 · Type 2 Diabetes

    NCT06192108 · Eli Lilly and Company · 28 U.S. investigators

    $1.5Mresearch payments

32. Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

    Recruiting · Phase 2 · Small Bowel Adenocarcinoma

    NCT06835387 · Ipsen Biopharmaceuticals, Inc · 2 U.S. investigators

    $1.5Mresearch payments

33. A Study of LY4060874 in Healthy Participants

    Completed · Phase 1 · Healthy Participants

    NCT06709820 · Eli Lilly and Company · 1 U.S. investigator

    $1.5Mresearch payments

34. A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

    Active, not recruiting · Phase 1, Phase 2 · Multiple Myeloma

    NCT02773030 · Celgene Corporation · 18 U.S. investigators

    $1.5Mresearch payments

35. An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

    Terminated · Phase 4 · Colitis, Ulcerative

    NCT05369832 · E.r. Squibb & Sons, L.l.c. · 68 U.S. investigators

    $1.5Mresearch payments

36. A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity

    Completed · Phase 1 · Healthy

    NCT07232732 · Eli Lilly and Company · 3 U.S. investigators

    $1.5Mresearch payments

37. Long-term Extension of GTX-102 in Angelman Syndrome

    Terminated · Phase 3 · Angelman Syndrome

    NCT06415344 · Ultragenyx Pharmaceutical Inc. · 7 U.S. investigators

    $1.5Mresearch payments

38. Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females

    Completed · Phase 3 · Contraception

    NCT05461573 · Exeltis, USA Inc. · 44 U.S. investigators

    $1.5Mresearch payments

39. A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

    Completed · Phase 2 · Migraine

    NCT06323928 · H. Lundbeck A S · 28 U.S. investigators

    $1.5Mresearch payments

40. A Study of LY3981314 in Healthy Participants

    Active, not recruiting · Phase 1 · Healthy

    NCT07005284 · Eli Lilly and Company · 1 U.S. investigator

    $1.5Mresearch payments

41. A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

    Completed · Prostate Cancer

    NCT05467176 · Sumitomo Pharma America, Inc. · 67 U.S. investigators

    $1.5Mresearch payments

42. Post-Market Study to Assess iTind Safety in Comparison to UroLift

    Recruiting · Not applicable · Benign Prostatic Hyperplasia (BPH)

    NCT04757116 · Olympus Corporation of The Americas · 16 U.S. investigators

    $1.5Mresearch payments

43. A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

    Recruiting · Phase 3 · Small Cell Lung Cancer

    NCT06203210 · Daiichi Sankyo Inc. · 33 U.S. investigators

    $1.5Mresearch payments

44. A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

    Recruiting · Phase 3 · Lung Transplant Rejection

    NCT06082037 · Sanofi US Services Inc. · 30 U.S. investigators

    $1.5Mresearch payments

45. Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

    Recruiting · Phase 2 · Waldenstrom Macroglobulinemia

    NCT06561347 · Beone Medicines USA, Inc. · 1 U.S. investigator

    $1.5Mresearch payments

46. Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

    Active, not recruiting · Phase 2 · Non-small Cell Lung Cancer

    NCT03916627 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $1.4Mresearch payments

47. A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

    Active, not recruiting · Phase 3 · Atopic Dermatitis

    NCT06389136 · AbbVie Inc. · 58 U.S. investigators

    $1.4Mresearch payments

48. A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

    Active, not recruiting · Phase 1, Phase 2 · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

    NCT05609370 · Beone Medicines USA, Inc. · 26 U.S. investigators

    $1.4Mresearch payments

49. Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

    Active, not recruiting · Phase 2 · Dermatitis Atopic

    NCT05769777 · Sanofi US Services Inc. · 28 U.S. investigators

    $1.4Mresearch payments

50. Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

    Active, not recruiting · Phase 1 · Hematologic Cancer

    NCT05753501 · AbbVie Inc. · 14 U.S. investigators

    $1.4Mresearch payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.